Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday ↗

March 08, 2024

U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.

Via Benzinga

Topics Stocks

ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗

March 06, 2024

ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

March 06, 2024

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...

Via Newsfile

Topics Economy

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

February 27, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

Analyst Expectations for Adaptimmune Therapeutics's Future ↗

August 10, 2023

Via Benzinga

Earnings Scheduled For March 6, 2024 ↗

March 06, 2024

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.

Via Benzinga

Adaptimmune Therapeutics Earnings Preview ↗

March 05, 2024

Via Benzinga

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

February 21, 2024

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining...

Via Newsfile

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 06, 2024

Via Benzinga

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

January 31, 2024

If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for...

Via Newsfile

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 29, 2024

Via Benzinga

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

January 04, 2024

Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...

Via Newsfile

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 15, 2023

Via Benzinga

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

December 06, 2023

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better...

Via Newsfile

Adaptimmune Receives Transfer of IND for Lete-cel Program

November 29, 2023

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma...

Via Newsfile

Adaptimmune Reports Third Quarter Financial Results and Business Update

November 08, 2023

Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission...

Via Newsfile

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

November 08, 2023

Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen...

Via Newsfile

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

October 31, 2023

~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...

Via Newsfile

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

October 31, 2023

40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had...

Via Newsfile

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

October 25, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in...

Via Newsfile

Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO

October 23, 2023

35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across...

Via Newsfile

Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

September 11, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces...

Via Newsfile

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 25, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 24, 2023

Via Benzinga

Adaptimmune Reports Second Quarter Financial Results and Business Update

August 09, 2023

Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell...

Via Newsfile

Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

August 03, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader...

Via Newsfile

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 01, 2023

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023Compelling clinical...

Via Newsfile

Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

May 25, 2023

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1...

Via Newsfile

Stocks That Hit 52-Week Lows On Friday ↗

July 28, 2023

Friday's session saw 59 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

June 06, 2023

On Tuesday, 69 stocks hit new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.